Integrity,Innovation,Reliability,Responsibility

Major Release|Phase IIa Clinical Trial Data for HP515 Tablets to Be Presented as a Late-Breaking Abstract at the American Association for the Study of Liver Diseases Annual Meeting

Time:2026-10-08 Source:海创药业 Hits:127

The Phase IIa clinical trial data (Study No. HP515-201) for HP515 tablets—a Class 1 innovative agent independently developed by Hinova Pharmaceuticals and intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as non-alcoholic steatohepatitis)—have been formally accepted by the American Association for the Study of Liver Diseases (AASLD) and will be presented as a Late-Breaking Abstract (poster) at The International Liver Congress / AASLD 2026 Annual Meeting.


This reflects the international academic community's high recognition of the clinical research achievements of the company's MASH innovative agent HP515 tablets, once again confirming the company's R&D capabilities in the field of innovative drugs for metabolic dysfunction-associated steatohepatitis (MASH).


American  Association  for  the  Study  of LiverDiseases, ASSLD

Founded in 1950, the American Association for the Study of Liver Diseases (AASLD) is the world's leading authoritative academic organization in the field of liver diseases, with members spanning hepatologists, researchers, and transplant specialists worldwide. The Association is primarily engaged in formulating and issuing guidelines for the diagnosis and treatment of liver diseases, publishing the authoritative journal Hepatology, and delivering medical education. It also hosts an annual scientific meeting each year, at which a large body of the latest clinical research findings and new-drug clinical trial data on hepatitis B, fatty liver, cirrhosis, liver cancer, and liver transplantation are presented. Key data for many novel liver-disease drugs are unveiled here for the first time, and much of the evidence underpinning subsequent clinical guidelines derives from the studies reported at this meeting—making it one of the highest-level global conferences in the liver disease community.


Late-Breaking Abstract


A Late-Breaking Abstract is a supplementary submission round and reporting format opened after the regular abstract deadline, reserved specifically for studies that have only just obtained complete data or important results. Acceptance into this category carries a high threshold and fierce competition; it represents highly time-sensitive research presentation at the meeting, often featuring the key results of new-drug clinical trials.


This time, HP515's acceptance by this authoritative international liver-disease organization, and its presentation as a Late-Breaking Abstract poster at this year's annual meeting, constitute the international academic community's high recognition of the clinical research achievements of the company's MASH innovative agent HP515 tablets. It represents the international liver-disease academic community's full affirmation of HP515's innovativeness and clinical value, and helps enhance the company's international academic influence.


The completed Phase I clinical trial of HP515 showed that HP515 met expectations in terms of safety, tolerability, pharmacokinetics, and pharmacodynamics. The results of this trial were presented in poster form at the International Liver Congress / EASL Congress 2026 (European Association for the Study of the Liver) in May 2026.


Previously, preclinical data on HP515 in combination with an agonist for obesity were presented as an oral report at the 32nd European Congress on Obesity (ECO) 2025, and were selected for poster presentation at The 3rd Obesity & Weight Loss Drug Development Summit in June 2025—both marking recognition of the relevant research data by top-tier international academic conferences.


About HP515


HP515 tablets are an orally available, highly selective, and highly potent THR-β (thyroid hormone receptor beta) agonist independently developed by the company. HP515 selectively activates the THR-β receptor, enhancing hepatocyte lipid metabolic activity and reducing hepatocyte lipid content, thereby achieving improvement of metabolic dysfunction-associated steatohepatitis (MASH). As of the disclosure date of this announcement, no product targeting the same mechanism has been approved for marketing in China.


HP515 was approved by China's National Medical Products Administration (NMPA) in August 2024 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and received approval from the U.S. Food and Drug Administration (FDA) for the same indication in September 2024. The company has completed the Phase IIa clinical trial in China, which met its primary and key secondary endpoints. The study results showed that HP515 tablets significantly improve hepatic fat metabolism and also improve dyslipidemia, with an overall favorable safety profile.


Overview of the MASH Indication:

Metabolic dysfunction-associated steatotic liver disease (MASLD or MAFLD) is a chronic, progressive liver disease arising from nutrient excess and insulin resistance in genetically susceptible individuals. The disease spectrum encompasses metabolic dysfunction-associated steatotic liver, metabolic dysfunction-associated steatohepatitis, and their associated fibrosis and cirrhosis [1]. MASH is the more severe subtype of MASLD and is a potentially progressive liver disease in which patients present with hepatomegaly, hepatic steatosis, increased inflammatory response, and increased liver fibrosis, which can further progress to cirrhosis, hepatocellular carcinoma, and death [2].


MASLD is the most common chronic liver disease worldwide, with a prevalence of 6.3%–45% among the general adult population, of whom 10%–30% have MASH. In most Asian countries, including China, the prevalence of MASLD is at a medium-to-high level (>25%). The global prevalence of MASH is 3%–5% [3], and the adult MASH prevalence in the United States can reach 5.8%. Changes in prevalence run parallel to the epidemics of obesity, type 2 diabetes, and metabolic syndrome. By 2030, the number of MASH patients in China is projected to reach 48.3 million [4], and in the United States to reach 27 million [5].


According to Frost & Sullivan data, the global MASH market is projected to reach US$32.2 billion by 2030, and the China MASH drug market is projected to reach RMB 35.5 billion by 2030.


About the Phase IIa Clinical Trial of HP515:


The Phase IIa clinical trial of HP515 is a multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study for metabolic dysfunction-associated steatohepatitis. The primary efficacy endpoint was the percent change in liver fat content (LFC) from baseline at Week 12, measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) and assessed by an independent third party. The final analysis showed that the mean LFC at Week 12 decreased by more than 50% from baseline in each dose group of HP515 tablets, compared with only a 3.5% decrease in the placebo group, a difference that was highly statistically significant (P < 0.001). In addition, lipid parameters including LDL-C, ApoB, non-HDL-C, TC, TG, and sd-LDL-C improved significantly relative to placebo (P < 0.001). Subjects were generally well tolerated, with no serious adverse events (SAEs) and no drug-related adverse events leading to discontinuation.


[1] Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the Prevention and Treatment of Metabolic (Non-alcoholic) Fatty Liver Disease (2024 Edition).
[2] Zobair M. Younossi. Non-alcoholic fatty liver disease – A global public health perspective [J]. Journal of Hepatology, 2019, vol. 70: 531–544.
[3] YOUNOSSI ZM, KOEING AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016, 64(1): 83–84.
[4] YaoRong Consulting, Market and R&D Landscape Analysis Report for the NASH Treatment Field.
[5] Le P, Tatar M, Dasarathy S, et al. Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1).


Disclaimer:

1. This article is intended to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not for advertising purposes. Hinova Pharmaceuticals does not make any recommendation, commitment, or guarantee regarding any drug or indication.

2. The information contained herein is derived from relevant research reports and clinical data and is for reference only. Please follow the guidance of physicians or other qualified healthcare professionals.

3. If any content in this article concerns information on products not yet marketed, such products are at the research, development, or clinical trial stage and are subject to uncertainty; the final outcome shall be subject to the approval of the National Medical Products Administration.